122 proof-checking-postdoc-computer-science-logic Fellowship positions at Nature Careers
Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Field
-
Postdoctoral Research Fellowship: Endothelial Basis of Cardiometabolic Disease Center for Pulmonary and Vascular Biology The laboratory of Dr. Philip Shaul and Dr. Chieko Mineo in the Center
-
collaborative and interdisciplinary environment. For more information about the exciting work we do, check out our publications (https://bhattacharya-lab.faculty.unlv.edu/publications/). Key Responsibilities
-
a single PDF file by email to: postdoc@smart.org.cn . The email subject should be "Applied Position + Full Name + Research Direction." Upon receipt of your materials, we will contact you promptly
-
, or computer science, or MD with comparable research experience Considerable experience in computer programming and computational biological applications. A strong background in statistics and biology. Experience
-
Post-Doctoral Research Fellow – Experimental Neuropathology Unit Department: Biomedical Sciences PI Reference: Martina Absinta Location: Humanitas University, Rozzano (MI), Italy Contract Type
-
. News World University Rankings by Subject, NTU was ranked 2nd in the world for Artificial Intelligence (AI) and Computer Science. It also ranked 5th in the world and 1st in Asia for Data Science and
-
computational biology and immunology are also welcome. Our laboratory focus ranges from the study of basic biological processes to very translational bench-to-clinical research with implementation of laboratory
-
X: @KAUST_News LinkedIn: KAUST (King Abdullah University of Science and Technology) Fellowship info Accepting applications between: 01 July 2025 – 15 January 2026 Deadline: 15th January 2026 Location
-
Requirements Postdoctoral researchers who have been engaged in biology and medical research in the U.S. but are no longer able to stay in the U.S., or those who were appointed to join a laboratory in the field
-
oncology grouping sees close to 550 new cases of these cancers a year. There is a large active clinical trials programme that spans phase 1 to phase 3. These patients have a poor prognosis, and this clinic